Manhattan Street Capital

Manhattan Street Capital operates an online fundraising platform that connects investors with high-performing midmarket companies and select startups. The platform utilizes the SEC's Regulation A+ to facilitate capital raising for these businesses, while also supporting various funding mechanisms such as Direct Listings, Regulation D, and Regulation S. Additionally, Manhattan Street Capital plays an active role in the initial public offering (IPO) process, enabling companies to navigate their funding needs effectively. The platform also accommodates Initial Coin Offerings that adhere to regulatory standards, ensuring they qualify as legitimate securities offerings. Through its services, Manhattan Street Capital aims to streamline the connection between interested investors, businesses, and service providers.

Kim Folsom

Co-Founder

1 past transactions

Biologx

Seed Round in 2020
Biologx has undertaken the mission of ensuring accessibility and affordability for life-saving insulin. In their pursuit of making high-quality insulin affordable, BiologX dedicated significant effort to eradicating inefficiencies across the production process. The company has developed distinctive methodologies for manufacturing recombinant human insulin (RHI), facilitating the production of greater insulin volumes within shorter timeframes. This achievement is realized while ensuring affordable pricing for patients globally. BiologX guarantees that their life-saving insulin products will not only meet but also surpass the rigorous USP Reference Standards, signifying the utmost quality within the industry. This endeavor is undertaken with the simultaneous aim of sustaining profits and fostering expansion.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.